RECRUITING

YAG Laser Vitreolysis for Vitreous Floaters

Talk to us

Conditions

Posterior Vitreous DetachmentMyopic VitreopathyVISION DEGRADING MYODESOPSIA

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters". In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.

Official Title

Therapeutic Neodymium-doped Yttrium-Aluminum-Garnet (Nd:YAG) Laser Vitreolysis for Vitreous Floaters - A Study to Quantify Visual Quality of Life, Vitreous Structure, and Vision Before and After Nd:YAG Laser Vitreolysis in Patients With Vision Degrading Myodesopsia

Quick Facts

Study Start:2023-10-17
Study Completion:2026-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06915922

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Only one eye per patient will be included in this study
  2. * Able and willing to give informed consent
  3. * Age ≥18 years
  4. * Suffering from symptomatic vitreous floaters
  5. * Floaters arising from either/both:
  6. * myopic vitreopathy
  7. * posterior vitreous detachment
  8. * Floaters meeting the following characteristics:
  9. * Present for ≥3 months
  10. * One single or more dense and well-defined vitreous opacities,
  11. * A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens
  12. * Visible on contact lens biomicroscopy
  1. * Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens)
  2. * Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study
  3. * Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator
  4. * Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator
  5. * Have synchysis scintillans (unusual vitreous opacities from old blood)
  6. * Have asteroid hyalosis (unusual vitreous opacities from cholesterol)
  7. * Have vitreous hemorrhage (fresh blood in the center of the eye)
  8. * Have active photopsia (flashing lights)
  9. * History of previous YAG laser vitreolysis treatments, or vitrectomy for any condition (retinal detachment, proliferative diabetic retinopathy, etc.)
  10. * Have Posterior Vitreous Detachment (separation of vitreous away from the retina lining the inside of the back of the eye) within the past 3 months
  11. * Are unable to attend study appointments
  12. * Have any other significant ocular or non-ocular condition that, at the discretion of the study investigator, puts the subject at risk or influences the results of the study
  13. * History of intraocular surgery within 6 months from study entry
  14. * History of retinal laser within 2 months from study entry

Contacts and Locations

Study Contact

Dr Jerry Sebag, MD, FACS, FRCOphth, FARVO
CONTACT
714-901-7777
JSebag@vmrinstitute.com

Study Locations (Sites)

VMR Institute for Vitreous Macula Retina
Huntington Beach, California, 92647
United States

Collaborators and Investigators

Sponsor: VMR Consulting, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-17
Study Completion Date2026-05

Study Record Updates

Study Start Date2023-10-17
Study Completion Date2026-05

Terms related to this study

Additional Relevant MeSH Terms

  • Posterior Vitreous Detachment
  • Myopic Vitreopathy
  • VISION DEGRADING MYODESOPSIA